A unique approach for discovering new autophagy therapeutics
The Lysoseeker™ Platform
An unbiased, data-driven approach to discover new biology.
Lysoseeker™ is a set of capabilities which goes from screen to drug via new mechanisms and disease utility.
We start with an unbiased phenotypic screen and use proprietary technologies to understand the mechanisms and targets of the autophagy-inducing molecules we identify.
We also screen these new molecules in a variety of translatable cellular models of disease.
With Lysoseeker™ we have discovered several highly promising lead molecules which are being optimised towards the clinic and restore autophagy in vivo via completely novel biology.
The process of autophagy features multiple steps and is highly dynamic.
We are building an understanding of these processes at a transcriptional and proteomic level and probing them with molecules to discover new intervention points, with the goal of boosting the whole process.
Our unbiased approach is leading to numerous opportunities for intervention.
We caught up with Senior Scientists Gabriela Vilema Enríquez and Matthew Williamson on their work within the neuroscience team at Samsara.
CMT Research Foundation and Samsara Therapeutics Partner on a Novel Therapeutic Approach for CMT1A with the Potential to Reach Clinical Trials
Hear from Nicole Mak, a Biology student at Bath University, on her year in industry with Samsara.
Michael Schlossmacher, Susan Perlman, Ed Tate and Christian Behl to help advance development of neurodegeneration and rare genetic disease therapeutics